Dawid T Janczak1, Malgorzata K Mimier2, Robert D McBane3, Patrick S Kamath4, Benjamin S Simmons3, Dalene M Bott-Kitslaar3, Charles J Lenz3, Emily R Vargas5, David O Hodge5, Waldemar E Wysokinski6. 1. Faculty of Health Science, Division of Oncology and Palliative Care, Wroclaw Medical University, Poland. 2. Department and Clinic of Ophthalmology, Wroclaw Medical University, Poland. 3. Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. 4. Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN. 5. Department of Health Sciences Research, Mayo Clinic, Jacksonville, FL. 6. Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: wysokinski.waldemar@mayo.edu.
Abstract
OBJECTIVES: To assess the outcome of direct oral anticoagulants (DOACs), specifically Xa inhibitors: rivaroxaban and apixaban, for the treatment of venous thromboembolism (VTE) of atypical location (VTE-AL), portal, mesenteric, hepatic, splenic, gonadal, renal, and cerebral veins, prospectively collected data of Mayo Thrombophilia Clinic Registry were used. METHODS: Patients with acute VTE-AL treated with DOACs, enrolled between March 1, 2013, and February 1, 2017, were compared with patients with VTE of typical location (VTE-TL: deep vein thrombosis of extremities and/or pulmonary embolism) receiving DOACs and with patients with VTE-AL treated with enoxaparin. RESULTS: Out of 623 patients with acute VTE receiving the study drug within 14 days of diagnosis, there were 63 with VTE-AL: 36 on DOAC, 23 on enoxaparin, and 4 on warfarin; 352 received DOAC for VTE-TL. The VTE-AL treated with DOAC/enoxaparin included the following: splanchnic (26/22), ovarian (8/2), renal (3/5), and cerebral veins (1/1), respectively. Recurrence rate (per 100 person-years) for the VTE-AL group receiving DOAC was 7.3, which was not different when compared with those for VTE-TL (2.4; P=.13) and VTE-AL groups receiving enoxaparin (23.7; P=.37). Major bleeding rate in the VTE-AL group receiving DOAC was not different compared with those for VTE-TL (7.2 vs 3.0; P=.26) and VTE-AL groups on enoxaparin (22.4; P=.31). Mortality was higher in the VTE-AL group on DOAC compared with the VTE-TL group (21.45 [95% CI, 7.87-46.69] vs 8.26 [95% CI, 5.35, 12.20]; P=.03). All patients with VTE-AL with events had cancer. CONCLUSION: The VTE recurrence and bleeding rates for rivaroxaban and apixaban used in VTE-AL are not different from those in patients with VTE-TL and similar to that for enoxaparin.
OBJECTIVES: To assess the outcome of direct oral anticoagulants (DOACs), specifically Xa inhibitors: rivaroxaban and apixaban, for the treatment of venous thromboembolism (VTE) of atypical location (VTE-AL), portal, mesenteric, hepatic, splenic, gonadal, renal, and cerebral veins, prospectively collected data of MayoThrombophilia Clinic Registry were used. METHODS:Patients with acute VTE-AL treated with DOACs, enrolled between March 1, 2013, and February 1, 2017, were compared with patients with VTE of typical location (VTE-TL: deep vein thrombosis of extremities and/or pulmonary embolism) receiving DOACs and with patients with VTE-AL treated with enoxaparin. RESULTS: Out of 623 patients with acute VTE receiving the study drug within 14 days of diagnosis, there were 63 with VTE-AL: 36 on DOAC, 23 on enoxaparin, and 4 on warfarin; 352 received DOAC for VTE-TL. The VTE-AL treated with DOAC/enoxaparin included the following: splanchnic (26/22), ovarian (8/2), renal (3/5), and cerebral veins (1/1), respectively. Recurrence rate (per 100 person-years) for the VTE-AL group receiving DOAC was 7.3, which was not different when compared with those for VTE-TL (2.4; P=.13) and VTE-AL groups receiving enoxaparin (23.7; P=.37). Major bleeding rate in the VTE-AL group receiving DOAC was not different compared with those for VTE-TL (7.2 vs 3.0; P=.26) and VTE-AL groups on enoxaparin (22.4; P=.31). Mortality was higher in the VTE-AL group on DOAC compared with the VTE-TL group (21.45 [95% CI, 7.87-46.69] vs 8.26 [95% CI, 5.35, 12.20]; P=.03). All patients with VTE-AL with events had cancer. CONCLUSION: The VTE recurrence and bleeding rates for rivaroxaban and apixaban used in VTE-AL are not different from those in patients with VTE-TL and similar to that for enoxaparin.
Authors: Danilo Pagliari; Rossella Cianci; Maria Gabriella Brizi; Francesco Antonio Mancarella; Massimiliano Musso; Marco Cintoni; Laura Franza; Roberto Antonio Flore; Antonio Gasbarrini; Paolo Tondi Journal: Intern Emerg Med Date: 2020-01-08 Impact factor: 3.397
Authors: Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Kevin Troy; Thomas Schiano; John Mascarenhas Journal: Blood Adv Date: 2020-02-25
Authors: Nichole E Brunton; Waldemar E Wysokinski; David O Hodge; Danielle T Vlazny; Damon E Houghton; Ana I Casanegra Journal: Res Pract Thromb Haemost Date: 2021-04-07
Authors: Leonard Naymagon; Douglas Tremblay; Nicole Zubizarreta; Erin Moshier; Steven Naymagon; John Mascarenhas; Thomas Schiano Journal: Inflamm Bowel Dis Date: 2021-01-19 Impact factor: 5.325